<DOC>
	<DOC>NCT00414050</DOC>
	<brief_summary>This study was conducted in healthy infants and will provide new immunogenicity and safety data for the modified process hepatitis B vaccine. This study was conducted to address the following: to evaluate the immunogenicity and safety data of the 5 microgram dose of the modified process hepatitis B vaccine compared with a 10 microgram dose of the modified process hepatitis B vaccine", to evaluate another dosing schedule of 2, 4, and 6 months, and to provide descriptive immunogenicity data of another marketed vaccine (ENGERIX-Bâ„¢).</brief_summary>
	<brief_title>A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject (Participant) is a healthy infant approximately 2 months of age Birth mother is a known carrier of hepatitis B virus or another known carrier has lived in close contact with the subject Subject's (Participant) birth mother did not receive any prenatal care Subject (Participant) has previous history of hepatitis B infection Subject (Participant) has been vaccinated against hepatitis B or birth mother was vaccinated within 6 months before birth of subject Subject (Participant) has had a fever within 72 hours of study start Subject (Participant) has received any bloodderived product or birth mother received bloodderived product within 6 months of birth of subject</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>2 Months</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>